| Description | IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2/M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity. |
| In vitro | IMS2186（0.3-10 μM；22小时）抑制人类成纤维细胞和人类癌细胞的增殖，其IC50分别为1.0-3.0 μM和0.3-3.0 μM。在10 ng/mL VEGF的刺激下，IMS2186（0-10 μM；22小时）抑制内皮形成，IC50为0.1-0.3 μM。IMS2186（0.1-10 μM；24小时）抑制巨噬细胞中炎症因子PGE2/TNF-a的产生，IC50为0.3-1 μM。IMS2186（0.1-10 μM；1.5小时）抑制巨噬细胞的迁移，IC50为1 μM[1]。 |
| In vivo | IMS2186（2.5毫克于0.5毫升；玻璃体注射；单剂量）对兔眼注射后没有显示眼部毒性。IMS2186（100微克/眼，即50微克/微升溶液剂量2.0微升；单剂量）在激光诱导的大鼠脉络膜新生血管（CNV）模型上展现出抗增殖作用[1]。 |
| molecular weight | 296.32 |
| Molecular formula | C18H16O4 |
| CAS | 1031206-36-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 60 mg/mL (202.48 mM), Sonication is recommended. |
| References | 1. Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33(7):599-609. |